In addition to the combined analysis of the MTV and GCB/ABC status or BCL2/MYC expression25, it appears relevant to obtain both cfDNA and MTV at baseline to risk stratify newly diagnosed DLBCL. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.